Lower GI Series Market SizeShare Growth Trends andRegional Forecast to 2032: LowerGI Series Markeaa

Lower GI Series Market Overview

The Lower GI Series Market is a critical segmentwithin diagnostic imaging, focusing on the examination and diagnosis of lower gastrointestinal(GI) tract disorders. The lower GI series, commonlyreferred to as a barium enema test, uses X-rays anda contrast material to visualize the large intestine,rectum, and sigmoid colon. This diagnostictechnique is widely utilized for detecting abnormalities such as polyps, diverticulitis,colorectal cancer, inflammatory bowel disease (IBD),and other structural or functional disorders. Theincreasing prevalence of GI-related diseases, rising geriatric populations, and advancements indiagnostic imaging technology are key drivers for the market’s growth.

In 2023, the lower GI series market was valued atapproximately USD 1.8 billion, with a projected compound annual growth rate (CAGR) of 6.2% from2023 to 2030. North America and Europe dominatethe market due to the widespread adoption ofadvanced diagnostic technologies, whileAsia-Pacificand Latin America are emerging regions withgrowing healthcare infrastructure andincreased awareness of early disease detection.

Market Size and Share

Key Drivers of Market Growth

1. Rising Incidence of GI Disorders
   The growing prevalence of gastrointestinaldisorders such as colorectal cancer, Crohn’s disease, and ulcerative colitis has significantlyincreased the demand for lower GI series diagnostic procedures.
2. Aging Population
   Older adults are more prone to GI tract diseases, and the aging global population has fueled the need for diagnostic imaging.
3. Technological Advancements
   Innovations in imaging technologies, such as digital radiography and automated contrast material delivery systems, have improved the accuracy and efficiency of lower GI series procedures.
4. Increased Health Awareness
   Public health initiatives and awareness campaigns about early cancer detection have encouraged routine screenings, boosting the demand for diagnostic tests like the lower GI series.